Recs

2

This Expense Could Wipe You Out

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.

Fidelity Investments' latest annual estimate for what an average couple will spend in retirement on health care totals $230,000. That figure may have fallen 8% from last year's quarter of a million dollars, but don't expect many more declines in the future.

Mmm ... doughnuts ...
We can't even credit the estimate's drop to lower health care prices. Instead, it owes largely to recent reform legislation that fills in the Medicare "doughnut hole."

Previously, Medicare coverage for seniors' prescription drugs suffered from a great big gap. Medicare would cover annual expenses up to $2,830, and then kick in again for any out-of-pocket expenses exceeding $4,550 -- but for any spending between those two sums, seniors were on their own. The reform will gradually phase out the doughnut hole; in the meantime, the government made a deal with big drug companies to offer discounts to Medicare recipients who fall within its boundaries.

While this reform is great in some respects, it's not all rosy for companies -- or individuals. Abbott Labs (NYSE: ABT  ) , for example, expects to lose $200 million in revenue because of the reform laws. The folks at Bloomberg estimated late last year that big pharmaceutical companies would offer more than $2 billion in discounts under their deal with the government. In 2009, Pfizer (NYSE: PFE  ) led the pack in drug spending for customers falling into the doughnut hole, at $469 million, followed by AstraZeneca (NYSE: AZN  ) with $400 million and Bristol-Myers Squibb (NYSE: BMY  ) at $368 million.

Prepare ... and hope
The best way to deal with this massive looming expense is to prepare well for it, by saving and investing effectively for retirement. It's fair to hope that further reforms will lighten our health-care costs, but it's not prudent to count on that. The closing of the doughnut hole is great, but drugmakers will likely find ways to compensate for that lost revenue -- perhaps, in part, by raising whatever prices they can.

Those of us who look forward to retiring comfortably need to keep health-care expenses in mind when planning ahead. Most of us will need large nest eggs to live off. In the meantime, though, at least we can all raise a doughnut to a rare year in which estimated health-care costs actually fell.

Longtime Fool contributor Selena Maranjian does not own shares of any companies mentioned in this article. Pfizer is a Motley Fool Inside Value recommendation. The Fool and Motley Fool Alpha LLC own shares of Abbott Laboratories. Try any of our investing newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is Fools writing for Fools.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1469482, ~/Articles/ArticleHandler.aspx, 8/21/2014 4:40:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Selena Maranjian
TMFSelena

Selena Maranjian has been writing for the Fool since 1996 and covers basic investing and personal finance topics. She also prepares the Fool's syndicated newspaper column and has written or co-written a number of Fool books. For more financial and non-financial fare (as well as silly things), follow her on Twitter...

Today's Market

updated 7 hours ago Sponsored by:
DOW 16,979.13 59.54 0.35%
S&P 500 1,986.51 4.91 0.25%
NASD 4,526.48 -1.03 -0.02%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/20/2014 4:00 PM
ABT $42.14 Down -0.40 -0.94%
Abbott Laboratorie… CAPS Rating: *****
AZN $71.00 Up +0.48 +0.68%
AstraZeneca plc (A… CAPS Rating: ***
BMY $50.04 Down -0.26 -0.52%
Bristol-Myers Squi… CAPS Rating: ****
PFE $28.89 Down -0.05 -0.17%
Pfizer CAPS Rating: ****

Advertisement